Arcus Biosciences (RCUS) Cash & Equivalents (2017 - 2026)
Arcus Biosciences' Cash & Equivalents was $150 million in Q2 2026, down 39.5% from $248 million a year earlier and down 25.4% from the prior quarter.
Arcus Biosciences (RCUS) Cash & Equivalents (2017 - 2026) Analysis & Trends
At the end of FY2025, Cash & Equivalents at Arcus Biosciences came in at $222 million, up 48.0% from FY2024.
- Cash & Equivalents shows a five-year compound annual growth rate of 5.1% (FY2020 to FY2025).
- In earlier years, Cash & Equivalents was $150 million in FY2024 (+18.1%), $127 million in FY2023 (-38.3%), $206 million in FY2022 (+39.2%) and $148 million in FY2021 (-14.7%).
- Quarterly Cash & Equivalents has moved between $127 million (Q4 2023) and $549 million (Q1 2022) over five years.
- Compared with a year earlier, Cash & Equivalents was higher in seven of the last eight quarters, with growth averaging 15.2%.
- The best year-over-year quarter for Cash & Equivalents over five years was Q2 2025 (growth of 59.0%); the worst was Q1 2023 (a decline of 56.6%).
- Per Business Quant data, RCUS's Cash & Equivalents in the three quarters before Q2 2026 was $201 million (Q1 2026), $222 million (Q4 2025) and $238 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,082.65 Bn | 1,051.23 Bn | 19.71 Bn | 8.95 Bn |
| 2 | Johnson & Johnson | 623.68 Bn | 542.21 Bn | 17.26 Bn | 20.42 Bn |
| 3 | AbbVie | 459.43 Bn | 432.59 Bn | 12.70 Bn | 6.57 Bn |
| 4 | Merck | 354.80 Bn | 309.23 Bn | 12.21 Bn | 6.85 Bn |
| 5 | Novartis Ag | 269.16 Bn | 225.03 Bn | 11.24 Bn | 7.62 Bn |
| 6 | Astrazeneca | 244.40 Bn | 217.97 Bn | 12.86 Bn | 4.89 Bn |
| 7 | Amgen | 220.17 Bn | 175.57 Bn | 7.24 Bn | 13.99 Bn |
| 8 | Gilead Sciences | 183.05 Bn | 157.16 Bn | 6.22 Bn | 3.18 Bn |
| 9 | Pfizer | 160.27 Bn | 107.22 Bn | 10.94 Bn | 976.00 Mn |
| 10 | Arcus Biosciences | 3.20 Bn | -133.06 Mn | - | 150.00 Mn |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 150.00 Mn |
| Mar 31, 2026 | 201.00 Mn |
| Dec 31, 2025 | 222.00 Mn |
| Sep 30, 2025 | 238.00 Mn |
| Jun 30, 2025 | 248.00 Mn |
| Mar 31, 2025 | 192.00 Mn |
| Dec 31, 2024 | 150.00 Mn |
| Sep 30, 2024 | 201.00 Mn |
| Jun 30, 2024 | 156.00 Mn |
| Mar 31, 2024 | 185.00 Mn |
| Dec 31, 2023 | 127.00 Mn |
| Sep 30, 2023 | 184.00 Mn |
| Jun 30, 2023 | 230.00 Mn |
| Mar 31, 2023 | 238.00 Mn |
| Dec 31, 2022 | 206.00 Mn |
| Sep 30, 2022 | 218.00 Mn |
| Jun 30, 2022 | 273.00 Mn |
| Mar 31, 2022 | 549.00 Mn |
| Dec 31, 2021 | 148.00 Mn |
| Sep 30, 2021 | 179.43 Mn |
Arcus Biosciences Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=RCUS&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "RCUS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=RCUS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();